EQRXライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (9 11月 2023 @ 06:00):

EQRx, Inc., a pharmaceutical company, engages in developing medicines primarily for the treatment of oncology and immune-inflammatory diseases in the United States...

Stats
本日の出来高	11.93M
平均出来高	2.95M
時価総額	1.14B
EPS	$-0.180 ( 2023-11-09 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-4.25
ATR14	$0.0660 (2.82%)

Insider Trading

Date	Person	Action	Amount	type
2023-11-09	Casdin Eli	Sell	5 488 164	Common Stock
2023-11-09	Casdin Eli	Sell	8 110 001	Warrants to purchase Class A Common Stock (right to buy)
2023-11-09	Casdin Eli	Sell	755 766	Earn-out Shares
2023-11-09	Casdin Eli	Sell	101 010	Stock Option (Right to Buy)
2023-11-09	Nallicheri Melanie	Buy	626 999	Common Stock

INSIDER POWER
-96.18
Last 94 transactions
Buy: 76 186 838 \| Sell: 93 441 879

ボリューム相関

長: 0.04 (neutral)

短: -0.25 (neutral)

Signal:(55.606) Neutral

EQRx, Inc. 相関

10 最も正の相関
BSRR	0.931
MPAA	0.931
CLGN	0.931
ENG	0.929
CNSP	0.929
CPTN	0.927
VBTX	0.926
MYFW	0.926
UBFO	0.925
BPYPN	0.924

10 最も負の相関
RMBS	-0.899
LYTS	-0.898
DSPG	-0.897
CCRC	-0.895
KE	-0.894
JMPNZ	-0.893
ISDX	-0.893
PPYAU	-0.892
IEUS	-0.891
HEWG	-0.89

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

EQRx, Inc. 相関 - 通貨/商品

-0.54
( weak negative )

0.20
( neutral )

0.00
( neutral )

-0.25
( neutral )

0.52
( weak )

0.49
( neutral )

EQRx, Inc. 財務諸表

Annual	2022
収益:	$0
総利益:	$0 (0.00 %)
EPS:	$0.430

FY	2022
収益:	$0
総利益:	$0 (0.00 %)
EPS:	$0.430

FY	2021
収益:	$0.00
総利益:	$0.00 (0.00 %)
EPS:	$-0.205

FY	2020
収益:	$0.00
総利益:	$0.00 (0.00 %)
EPS:	$-0.513

Financial Reports:

No articles found.

EQRx, Inc.

EQRx, Inc., a pharmaceutical company, engages in developing medicines primarily for the treatment of oncology and immune-inflammatory diseases in the United States. The company's pre-registrational programs in Phase III clinical trial include Aumolertinib, an epidermal growth factor receptor (EGFR) inhibitor for the treatment of patients with EGFR-mutated non-small cell lung cancer (NSCLC); and Sugemalimab, an anti-programmed death-ligand 1 antibody for the treatment of Stage III and Stage IV NSCLC. Its other programs in pipeline include clinical and pre-clinical stage assets, which comprise Lerociclib, a small molecule cyclin-dependent kinase 4/6 inhibitor, which is in Phase II clinical trials in patients with metastatic breast cancer; EQ176, an anti-programmed death-1 antibody that is in Phase III trials for the treatment of patients with primary liver cancer; and EQ121, a selective janus kinase-1 inhibitor that is in various Phase I trials. The company was incorporated in 2019 and is headquartered in Cambridge, Massachusetts.